SCHEMBL4336090

SCHEMBL4336090

c1ccc2oc(-c3cn4nccc4nc3NCc3ccncc3)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.51
FYN P06241 1/20 0.51
IRAK1 P51617 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
CDK2 P24941 1/20 0.36
JAK2 O60674 1/20 0.36
HTR2C P28335 1/20 0.36
RET P07949 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
NPC1 O15118 3/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
FLT1 P17948 1/20 0.35
KDR P35968 1/20 0.35
KCNN1 Q92952 1/20 0.35
KCNN2 Q9H2S1 1/20 0.35
KCNN3 Q9UGI6 1/20 0.35
CYP11B1 P15538 1/20 0.35
ALDH1A1 P00352 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4595114 0.80 MKNK1 (0.50) MKNK1HTR2CMAOAMAOBNPC1
SCHEMBL4338918 0.78 MAOA (0.40) HTR2CMAOAMAOBNPC1ALDH1A1
SCHEMBL2950873 0.74 MKNK1 (0.64) MKNK1FYN
SCHEMBL4336096 0.74 RET (0.67) MKNK1FYNRET
SCHEMBL2950868 0.72 MKNK1 (0.56) MKNK1FYNJAK2RETMAOA
SCHEMBL4342512 0.71 TUBB4A (0.40) JAK2MAOBLMNAFLT1KDR
SCHEMBL4336105 0.70 MKNK1 (0.56) MKNK1FYNRETNPC1CYP11B1
SCHEMBL4595321 0.70 PRKCQ (0.39) MAOAMAOBFLT1KDRALDH1A1
SCHEMBL17981122 0.70 FYN (0.48) MKNK1FYNCDK2MAOAMAOB
SCHEMBL2950870 0.67 MKNK1 (1.00) MKNK1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049539-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. Bayer Schering Pharma Aktiengesellschaft (DE) 2009-04-22 EP claimed
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-02-14 US claimed
EP-1873157-A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-02 EP claimed
WO-2007147647-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO claimed
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-02-14 US disclosed
EP-1873157-A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME DPYD, FLT1, PDXK MKNK1 2469/4885FYN 151/4885IRAK1 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.